The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a ...

In this article, we explore how aging impacts the musculoskeletal system and share expert-backed prevention tips to help you ...

Osteoporosis, often called a silent disease, weakens bones and increases the risk of fractures, making it a leading cause of ...

In a Korean national study, osteoporotic fracture was associated with higher risks for graft failure and death among kidney transplant recipients. Bone fracture from osteoporosis in kidney transplant ...

Women's Health Therapeutics Market Rising Awareness and Government Initiatives Drive Growth AUSTIN, TX, UNITED STATES, February 28, 202 ...

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...

biosimilar candidate of PROLIA/XGEVA (denosumab). The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.BASEL, Switzerland and ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...